Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

BACKGROUND: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, real-world experience is limited. OBJECTIV...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Respiration
Egile Nagusiak: Brunnemer, Eva, Wälscher, Julia, Tenenbaum, Svenja, Hausmanns, Julia, Schulze, Karen, Seiter, Marianne, Heussel, Claus Peter, Warth, Arne, Herth, Felix J.F., Kreuter, Michael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: S. Karger AG 2018
Gaiak:
Clinical Investigations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5985741/
https://ncbi.nlm.nih.gov/pubmed/29490307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000485933
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak